Sunovion Pharmaceuticals has announced that all 4 dose levels of its SUN-101 glycopyrrolate inhalation solution tested in a Phase 2 study produced statistically significant improvements in lung function. The 28-day randomized, double-blind, placebo-controlled study involved more than 280 COPD patients and compared 12.5 mcg, 25 mcg, 50 mcg, and 100 mcg doses of SUN-101 and placebo delivered by the eFlow nebulizer. Data were presented at Chest 2014.
Lead Investigator Edward Kerwin, Medical Director of the Clinical Research Institute in Southern Oregon, commented, “While the efficacy and safety of SUN-101 have yet to be established, the data from this dose-ranging study illustrates that SUN-101 may be a potential treatment option for patients with moderate-to-severe COPD. It’s important to develop a nebulized long-acting muscarinic antagonist, which is not currently available, to ensure that patients have a variety of treatment options and can work with their healthcare provider to determine which treatments are most appropriate for them.”
Sunovion VP of Clinical Research and Medical Affairs Alistair Wheeler commented, “The SUN-101 clinical trial further supports nebulization as a potential treatment alternative to deliver medication for patients with moderate-to-severe COPD. The continued development of SUN-101 affirms Sunovion’s pledge to helping COPD patients and healthcare providers and addressing the evolving needs of the COPD community by investigating potential additional treatment options.”
Read the Sunovion press release.
